An evaluation of the methodological quality of published guidelines for the surgical treatment of pleural mesothelioma.
Journal
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
ISSN: 1473-5709
Titre abrégé: Eur J Cancer Prev
Pays: England
ID NLM: 9300837
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
23
10
2023
pubmed:
5
5
2023
entrez:
5
5
2023
Statut:
ppublish
Résumé
To benchmark their quality, a project was designed to analyze the methodology of previous guidelines and recommendations for malignant pleural mesothelioma projects. A narrative literature search was conducted, and each guideline was evaluated using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool and rated on a seven-point scale for its many items and domains. Six guidelines that met the inclusion requirements were evaluated. Due to greater development rigor and editorial independence, the engagement of scientific societies was associated with an improvement in methodological quality. According to the standards of AGREE II, the methodological quality of earlier guidelines was relatively low. Nonetheless, two previously published guidelines could serve as a template for the establishment of the most effective methodological quality guidelines.
Sections du résumé
BACKGROUND
To benchmark their quality, a project was designed to analyze the methodology of previous guidelines and recommendations for malignant pleural mesothelioma projects.
METHODS
A narrative literature search was conducted, and each guideline was evaluated using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool and rated on a seven-point scale for its many items and domains.
RESULTS
Six guidelines that met the inclusion requirements were evaluated. Due to greater development rigor and editorial independence, the engagement of scientific societies was associated with an improvement in methodological quality.
CONCLUSION
According to the standards of AGREE II, the methodological quality of earlier guidelines was relatively low. Nonetheless, two previously published guidelines could serve as a template for the establishment of the most effective methodological quality guidelines.
Identifiants
pubmed: 37144594
doi: 10.1097/CEJ.0000000000000810
pii: 00008469-990000000-00064
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
512-iiInformations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
AGREE Collaboration (2003). Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 12:18–23.
ANS Consortium (2020). The AGREE II instrument [Electronic version]. http://www.agreetrust.org . [Accessed 20 May 2020]
Antoniou SA, Florez ID, Markar S, Logullo P, Lopez-Cano M, Silecchia G, et al. (2022). AGREE-S: AGREE II extension for surgical interventions: appraisal instrument. Surg Endosc 36:5547–5558.
Bertolaccini L, Zamprogna C, Barberis L, Navarra M, Manno E, D’Urso A, et al. (2007). Malignant pleural effusions: review of treatment and our experience. Rev Recent Clin Trials 2:21–25.
Bertolaccini L, Viti A, Terzi A (2014). To seed or not to seed: the open question of mesothelioma intervention tract metastases. Chest 146:e111.
Bertolaccini L, Bedetti B, Brunelli A, Marinova K, Raveglia F, Rocco G, et al. (2017). A benchmarking project on the quality of previous guidelines about the management of malignant pleural effusion from the European Society of Thoracic Surgeons (ESTS) Pleural Diseases Working Group. Eur J Cardiothorac Surg 52:356–362.
Bertolaccini L, Congedo MT, Bertani A, Solli P, Nosotti M (2018). A project to assess the quality of the published guidelines for managing primary spontaneous pneumothorax from the Italian Society of Thoracic Surgeons. Eur J Cardiothorac Surg 54:920–925.
Bertolaccini L, Casiraghi M, Petrella F, Rampinelli C, Tessitore A, Spaggiari L (2022). A methodological quality evaluation of the published guidelines and recommendations about the lung cancer screening. Eur J Cancer Prev 31:19–25.
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, et al. (2018). ERS/EACTS statement on the management of malignant pleural effusions. Eur Respir J 52:1800349.
Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. (2010). AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 182:E839–E842.
Kanayama M, Mori M, Matsumiya H, Taira A, Shinohara S, Takenaka M, et al. (2022). Surgical strategy for malignant pleural mesothelioma: the superiority of pleurectomy/decortication. Surg Today 52:1031–1038.
Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, et al. (2018). Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1343–1373.
Logullo P, Florez ID, Antoniou GA, Markar S, Lopez-Cano M, Silecchia G, et al. (2022). AGREE-S: AGREE II extension for surgical interventions - United European Gastroenterology and European Association for Endoscopic Surgery methodological guide. United European Gastroenterol J 10:425–434.
Lucchi M, Mussi A, Bertolaccini L, Crisci R (2018). The everlasting story of malignant pleural mesothelioma: where do we stand? J Thorac Dis 10:S192–S193.
Luckraz H, Rahman M, Patel N, Szafranek A, Gibbs AR, Butchart EG (2010). Three decades of experience in the surgical multi-modality management of pleural mesothelioma. Eur J Cardiothorac Surg 37:552–556.
Nadal E, Bosch-Barrera J, Cedres S, Coves J, Garcia-Campelo R, Guirado M, et al. (2021). SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Clin Transl Oncol 23:980–987.
Petrella F, Cocce V, Masia C, Milani M, Sale EO, Alessandri G, et al. (2017). Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells. Biomed Pharmacother 87:755–758.
Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. (2022). Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(☆). Ann Oncol 33:129–142.
R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing.
RStudio Team (2021). RStudio: integrated development environment for R. RStudio, Inc.
Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. (2020). ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J 55:1900953.
Viti A, Bertolaccini L, Terzi A (2015). Biologic therapy and gene therapy in the multimodality treatment of malignant pleural mesothelioma. Ann Transl Med 3:248.
Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, et al. (2018). British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 73:i1–i30.
Zhou N, Rice DC, Tsao AS, Lee PP, Haymaker CL, Corsini EM, et al. (2022). Extrapleural pneumonectomy versus pleurectomy/decortication for malignant pleural mesothelioma. Ann Thorac Surg 113:200–208.